These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 35767448)
1. Ivosidenib and Azacitidine in IDH1-Mutated AML. Gil-Sierra MD; Briceño-Casado MP; Sierra-Sanchez JF N Engl J Med; 2022 Jun; 386(26):2535-2536. PubMed ID: 35767448 [No Abstract] [Full Text] [Related]
2. Ivosidenib and Azacitidine in IDH1-Mutated AML. Goodman AM; Mohyuddin GR; Prasad V N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449 [No Abstract] [Full Text] [Related]
3. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply. Montesinos P; de Botton S; Döhner H N Engl J Med; 2022 Jun; 386(26):2536-2537. PubMed ID: 35767450 [No Abstract] [Full Text] [Related]
4. Ivosidenib and Azacitidine in Montesinos P; Recher C; Vives S; Zarzycka E; Wang J; Bertani G; Heuser M; Calado RT; Schuh AC; Yeh SP; Daigle SR; Hui J; Pandya SS; Gianolio DA; de Botton S; Döhner H N Engl J Med; 2022 Apr; 386(16):1519-1531. PubMed ID: 35443108 [TBL] [Abstract][Full Text] [Related]
5. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and Wang L; Song J; Xiao X; Li D; Liu T; He X J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456 [TBL] [Abstract][Full Text] [Related]
6. Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia? Takahashi K Anticancer Agents Med Chem; 2023; 23(8):864-866. PubMed ID: 36503457 [No Abstract] [Full Text] [Related]
7. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220 [TBL] [Abstract][Full Text] [Related]
8. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479 [TBL] [Abstract][Full Text] [Related]
9. Evaluating ivosidenib for the treatment of acute myeloid leukemia. Donker ML; Ossenkoppele GJ Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831 [TBL] [Abstract][Full Text] [Related]
10. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938 [TBL] [Abstract][Full Text] [Related]
11. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803 [TBL] [Abstract][Full Text] [Related]
12. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853 [TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099 [TBL] [Abstract][Full Text] [Related]
14. Ivosidenib Boosts OS with Azacitidine in AML. Cancer Discov; 2022 Jul; 12(7):1602-1603. PubMed ID: 35532213 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with Bewersdorf JP; Patel KK; Goshua G; Shallis RM; Podoltsev NA; Stahl M; Stein EM; Huntington SF; Zeidan AM Leuk Lymphoma; 2023 Feb; 64(2):454-461. PubMed ID: 36493798 [TBL] [Abstract][Full Text] [Related]
16. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251 [TBL] [Abstract][Full Text] [Related]
17. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467 [TBL] [Abstract][Full Text] [Related]
18. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Roboz GJ; DiNardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP; Mannis GN; Pollyea DA; Stein AS; Uy GL; Watts JM; Fathi AT; Kantarjian HM; Tallman MS; Choe S; Dai D; Fan B; Wang H; Zhang V; Yen KE; Kapsalis SM; Hickman D; Liu H; Agresta SV; Wu B; Attar EC; Stone RM Blood; 2020 Feb; 135(7):463-471. PubMed ID: 31841594 [TBL] [Abstract][Full Text] [Related]
19. Ivosidenib: First Global Approval. Dhillon S Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701 [TBL] [Abstract][Full Text] [Related]
20. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]